Research on Development Strategies of Traditional Chinese Medicine Enterprises Based on SWOT Analysis

Hong-wu ZHANG; Wen-long HUANG

doi:10.13422/j.cnki.syfjx.20201946

您当前的位置：

首页 >

文章列表页 >

Research on Development Strategies of Traditional Chinese Medicine Enterprises Based on SWOT Analysis

Pharmacy Administration | 更新时间：2020-09-09

- Research on Development Strategies of Traditional Chinese Medicine Enterprises Based on SWOT Analysis
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 26, Issue 17, Pages: 177-183(2020)
- 作者机构：
  
  中国药科大学，南京 210009
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20201946
  CLC： R22;F27;R28;R932
- Published Online：16 June 2020，
  
  Published：05 September 2020
- 稿件说明：
移动端阅览
张宏武,黄文龙.基于SWOT分析法的我国中药企业发展策略分析[J].中国实验方剂学杂志,2020,26(17):177-183.

ZHANG Hong-wu,HUANG Wen-long.Research on Development Strategies of Traditional Chinese Medicine Enterprises Based on SWOT Analysis[J].Chinese Journal of Experimental Traditional Medical Formulae,2020,26(17):177-183.
张宏武,黄文龙.基于SWOT分析法的我国中药企业发展策略分析[J].中国实验方剂学杂志,2020,26(17):177-183. DOI： 10.13422/j.cnki.syfjx.20201946.

ZHANG Hong-wu,HUANG Wen-long.Research on Development Strategies of Traditional Chinese Medicine Enterprises Based on SWOT Analysis[J].Chinese Journal of Experimental Traditional Medical Formulae,2020,26(17):177-183. DOI： 10.13422/j.cnki.syfjx.20201946.

摘要

中医药作为我国独特的卫生资源、潜力巨大的经济资源、具有原创优势的科技资源、优秀的文化资源和重要的生态资源，近年来在我国经济社会发展中成绩斐然。然而也要看到，改革发展中的中医药仍存在诸多问题，尤其是中药企业普遍研发创新意愿不足、研发成果转化能力差、长期“小众化”发展、中医药全球化水平不高等，这些问题都严重制约了我国中医药的健康全面发展。笔者以我国中药企业为研究对象，运用SWOT分析法对其优势、劣势、机遇和风险进行综合战略分析，得出我国中药企业应将经典名方复方制剂作为产品研发重点，进行中药产品研发创新，并提出产品研发创新的策略。

Abstract

Traditional Chinese medicine (TCM)

as the unique health resources

huge potential economic resources

scientific and technological resources with original advantages

excellent cultural resources and important ecological resources

has made remarkable achievements in Chinese economic and social development in recent years. However

there are still some problems in the reform and development of TCM

especially the lack of willingness to innovate and low ability in commercialization of research and development findings in such companies. Meanwhile

the globalization level of TCM is not high. All these problems have seriously restricted the overall development of TCM. Taking TCM enterprises as the research object

this paper uses SWOT analysis to carry out comprehensive strategic analysis on its advantages

disadvantages

opportunities and risks. It is concluded that TCM enterprises in China should focus on research and development of classical formula compound preparations and innovative TCM products

and then propose product development and innovation strategies.

关键词

Keywords

references

中共中央国务院 . 中医药发展战略规划纲要（ 2016 — 2030 年）[EB/OL]. http://www.gov.cn/zhengce/content/2016-02/26/content_5046678.htm http://www.gov.cn/zhengce/content/2016-02/26/content_5046678.htm ， 2016-02-22 / 2020-03-20 .

BERNROIDER E . Factors in SWOT analysis applied to micro，small-to-medium，and large software enterprises：an austrian study [J]. EMJ ， 2002 ， 20 ( 5 )： 562 - 573 .

黄昕，周世植 . 企业经营战略SWOT分析方法的改进及模型 [J]. 价值工程， 2000 ， 17 ( 3 )： 34 - 37 .

中华人民共和国国务院新闻办公室 . 《中国的中医药》白皮书 [EB/OL]. http://www.scio.gov.cn/ztk/dtzt/34102/35624/35628/Document/1534714/1534714.htm http://www.scio.gov.cn/ztk/dtzt/34102/35624/35628/Document/1534714/1534714.htm ， 2016-12-06 / 2020-03-20 .

周佳佳，芦柏震，周俐斐 . 医院中药制剂现状分析与展望——以浙江省肿瘤医院中药制剂为例 [J]. 中医药管理杂志， 2012 ， 20 ( 1 )： 72 - 73 .

金安琪，王诺，常冬，等 . 从科技驱动角度分析中药产业创新发展面临的问题与出路 [J]. 中国食品药品监管， 2019 （ 12 ）： 82 - 88 .

医药情报站的雪球原创专栏 . 2019 年中药中报一览： 67家中药企业上半年总营收1607亿元，近四成企业净利润下滑 [EB/OL]. https://xueqiu.com/5290320998/132852854 https://xueqiu.com/5290320998/132852854 ， 2019-09-16 / 2020-03-18 .

张宏武，黄文龙 . 从我国中药企业的现状看中医药的传承与发展 [J]. 中国卫生事业管理， 2020 ， 37 （ 3 ）： 193 - 196 .

邓盛木 . 论中医药文化建设对中医药院校教育人才培养的助推作用 [J]. 教育教学论坛， 2015 （ 20 ）： 51 - 52 .

养生经济 . 连花清瘟获得多国上市许可中医药大放异彩赢得全球认同 [EB/OL]. https://www.sohu.com/a/384734057_440946 https://www.sohu.com/a/384734057_440946 ， 2020-04-01 / 2020-04-10 .

李振飞，翟东升，冯秀珍，等 . 中药企业国际化知识产权协同分析——以津村株式会社和北京同仁堂为例 [J]. 情报杂志， 2015 ， 34 ( 7 )： 105 - 109 .

韩俊红 . 传统中医药海外发展的澳大利亚模式与启示 [J]. 广西民族大学学报：哲学社会科学版， 2019 ， 41 （ 6 ）： 88 - 96 .

国务院中医药工作部际联席会议办公室 . 中共中央国务院关于促进中医药传承创新发展的意见 [EB/OL]. http://bgs.satcm.gov.cn/zhengcewenjian/2019-12-16/12179.html http://bgs.satcm.gov.cn/zhengcewenjian/2019-12-16/12179.html ， 2019-12-16 / 2020-04-08 .

陈海波 . 建立中医药独立监管体系 [N]. 光明日报， 2016-03-15 （ 6 ）.

程蒙，杨光，李颖，等 . 《中国中药资源发展报告》简述 [J]. 中国食品药品监管， 2020 ， doi： 10.3969/j.issn.1673-5390.2020.01 http://dx.doi.org/10.3969/j.issn.1673-5390.2020.01 .

欧阳静 . 中国药用植物资源可持续发展的路径选择 [D]. 乌鲁木齐：新疆大学， 2006 .

熊长文 . 太极集团中药为本发展战略研究 [D]. 成都：西南财经大学， 2013 .

张宏武，黄文龙 . 基于五行理论分析企业家对企业药品研发能力的影响 [J]. 中国实验方剂学杂志， 2020 ， doi： 10.13422/j.cnki.syfjx.20201056 http://dx.doi.org/10.13422/j.cnki.syfjx.20201056 .

张鹏，刘安，邬兰，等 . 经典名方概述与开发探讨 [J]. 中国实验方剂学杂志， 2020 ， 26 （ 15 ）： 183 - 194 .

张家锡 . 中医学基础 [M]. 上海：上海科学技术文献出版社， 2001 ： 1 .

国家中医药管理局 . 全国中医药大会今天召开：我国中医药服务体系日益完善 [EB/OL]. http://www.satcm.gov.cn/xinxifabu/shizhengyaowen/2019-10-25/11629.html http://www.satcm.gov.cn/xinxifabu/shizhengyaowen/2019-10-25/11629.html ， 2019-10-25 / 2020-03-04 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Ecological Suitability Analysis of Production Areas and Industrial Development Strategy of Dai Medicine

Research and Development Strategy of Classical Formula Compound Preparation

miRNA in Coronary Heart Disease and Traditional Chinese medicine

Development Strategy Analysis of GMP Implementation for Manufacturing Enterprises of Topical Pharmaceutical Preparations

Related Author

Xiao-hui ZHANG

Ji-qing ZHANG

Chao-qun WANG

Lin-lin DONG

Xiao-ming SUN

Dong-xue LI

An LIU

Jing-tang CHEN

Related Institution

Institute of Literature in Chinese Medicine， Nanjing University of Chinese Medicine

Institute of Medical Information， Chinese Academy of Medical Science

Institute of Chinese Materia Medica，China Academy of Chinese Medical Sciences

Institute of Chinese Materia Medica, China Academy of Chinese Medical Science

China National Center for Biotechnology Development

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰